Article info

Download PDFPDF

Commentary
Response to commentary: Head-to-head trial of pegunigalsidase alfa versus agalsidase beta in patients with Fabry disease and deteriorating renal function: results from the 2-year randomised phase III BALANCE study – determination of immunogenicity

Authors

  1. Correspondence to Dr David G Warnock, Medicine, The University of Alabama at Birmingham, Birmingham, Alabama, USA; dwarnock{at}uab.edu
View Full Text

Citation

Warnock DG, Wallace EL
Response to commentary: Head-to-head trial of pegunigalsidase alfa versus agalsidase beta in patients with Fabry disease and deteriorating renal function: results from the 2-year randomised phase III BALANCE study – determination of immunogenicity

Publication history

  • Received January 12, 2024
  • Accepted January 15, 2024
  • First published April 8, 2024.
Online issue publication 
May 21, 2024

Article Versions

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.